

June 15, 2017

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra -Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market permission in Form 45 (Marketing Authorization) from Drug Controller General of India (DCGI) for FDC of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder (Symbicort® Turbuhaler® 320/9 µg).

This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder.

FDC of Budesonide 320 µg + Formoterol Fumarate Dihydrate 9 µg inhalation powder (**Symbicort® Turbuhaler® 320/9 µg**) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting β-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations.

Kindly take the same on record.

For AstraZeneca Pharma India Limited



Pratap Rudra

Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE

AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor
Manyata Embassy Business Park
Rachenahalli, Outer Ring Road
Bangalore - 560045, INDIA

TEL : +91 80 67748000

FAX : +91 80 67748857

CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY

12th Mile on Bellary Road
Venkata, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 67749000

FAX : +91 80 28462208
+91 80 67749628